Get started
Aurinia Pharmaceuticals IncAurinia Pharmaceuticals IncAurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

AUPH chart


Full chart

AUPH upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.16 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.16 USD
Net income (FY)
‪−78.02 M‬ USD
Revenue (FY)
‪175.51 M‬ USD
Shares float
‪128.71 M‬
Beta (1Y)
1.06

Employees


Employees (FY)
300
Change (1Y)
0
Revenue / Employee (1Y)
‪585.04 K‬ USD
Net income / Employee (1Y)
‪−260.07 K‬ USD

About Aurinia Pharmaceuticals Inc


Sector
Health Technology
Industry
Biotechnology
CEO
Peter S. Greenleaf
Website
auriniapharma.com
Headquarters
Edmonton
Founded
1993
FIGI
BBG000BCRJM5
Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

AUPH news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of AUPH is 8.24 USD — it has increased by 1.50% in the past 24 hours. Watch Aurinia Pharmaceuticals Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aurinia Pharmaceuticals Inc stocks are traded under the ticker AUPH.
AUPH stock has fallen by −3.79% compared to the previous week, the month change is a 12.92% rise, over the last year Aurinia Pharmaceuticals Inc has showed a −10.63% decrease.
We've gathered analysts' opinions on Aurinia Pharmaceuticals Inc future price: according to them, AUPH price has a max estimate of 13.00 USD and a min estimate of 8.00 USD. Watch AUPH chart and read a more detailed Aurinia Pharmaceuticals Inc stock forecast: see what analysts think of Aurinia Pharmaceuticals Inc and suggest that you do with its stocks.
AUPH reached its all-time high on Nov 3, 2021 with the price of 33.97 USD, and its all-time low was 1.00 USD and was reached on Sep 10, 2012. View more price dynamics on AUPH chart.
See other stocks reaching their highest and lowest prices.
AUPH stock is 4.42% volatile and has beta coefficient of 1.06. Track Aurinia Pharmaceuticals Inc stock price on the chart and check out the list of the most volatile stocks — is Aurinia Pharmaceuticals Inc there?
Today Aurinia Pharmaceuticals Inc has the market capitalization of ‪1.16 B‬, it has increased by 11.44% over the last week.
Yes, you can track Aurinia Pharmaceuticals Inc financials in yearly and quarterly reports right on TradingView.
Aurinia Pharmaceuticals Inc is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
AUPH earnings for the last quarter are 0.10 USD per share, whereas the estimation was 0.01 USD resulting in a 566.67% surprise. The estimated earnings for the next quarter are 0.03 USD per share. See more details about Aurinia Pharmaceuticals Inc earnings.
Aurinia Pharmaceuticals Inc revenue for the last quarter amounts to ‪67.77 M‬ USD, despite the estimated figure of ‪57.48 M‬ USD. In the next quarter, revenue is expected to reach ‪61.70 M‬ USD.
AUPH net income for the last quarter is ‪14.35 M‬ USD, while the quarter before that showed ‪722.00 K‬ USD of net income which accounts for ‪1.89 K‬% change. Track more Aurinia Pharmaceuticals Inc financial stats to get the full picture.
No, AUPH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 300.00 employees. See our rating of the largest employees — is Aurinia Pharmaceuticals Inc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aurinia Pharmaceuticals Inc EBITDA is ‪3.83 M‬ USD, and current EBITDA margin is −40.83%. See more stats in Aurinia Pharmaceuticals Inc financial statements.
Like other stocks, AUPH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aurinia Pharmaceuticals Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aurinia Pharmaceuticals Inc technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aurinia Pharmaceuticals Inc stock shows the buy signal. See more of Aurinia Pharmaceuticals Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.